{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:24:38Z","timestamp":1781889878434,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The aim of this study was to identify positive predictors for survival in uveal melanoma (UM) patients treated with percutaneous hepatic perfusion with melphalan (M-PHP), by retrospectively pooling data from three centers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and Methods<\/jats:title>\n                <jats:p>Retrospective analysis including patients (<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\">\n                    <mml:mo>\u2265<\/mml:mo>\n                  <\/mml:math><\/jats:alternatives><\/jats:inline-formula> 18\u00a0years) treated with M-PHP between February 2014 and December 2019 for unresectable liver-dominant or liver-only metastases from UM. Predictors for OS were assessed using uni- and multivariate analyses. Other study outcome measures were response rate, progression-free survival (PFS), liver progression-free survival (LPFS), overall survival (OS) and complications according to CTCAEv5.0.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 101 patients (47.5% males; median age 59.0\u00a0years) completed a minimum of one M-PHP. At a median follow-up time of 15.0\u00a0months, complete response (CR), partial response (PR), stable disease (SD) and progressive disease were seen in five (5.0%), 55 (54.5%), 30 (29.7%) and 11 (10.9%) patients, respectively, leading to a 89.1% disease control rate. Median PFS, LPFS and OS were 9.0, 11.0 and 20.0\u00a0months, respectively. Survival analyses stratified for radiological response demonstrated significant improved survival in patients with CR or PR and SD category. Treatment of the primary tumor with radiotherapy,\u2009\u2265\u20092\u00a0M-PHP and lactate dehydrogenase (LDH)\u2009&lt;\u2009248\u00a0U\/L were correlated with improved OS. Thirty-day mortality was 1.1% (<jats:italic>n<\/jats:italic>\u2009=\u20092). Most common complication was hematological toxicity (self-limiting in most cases).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>M-PHP is safe and effective in patients with UM liver metastases. Achieving CR, PR or SD is associated with improved survival. Primary tumor treatment with radiotherapy, normal baseline LDH and\u2009&gt;\u20091\u00a0M-PHP cycles are associated with improved OS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00270-022-03225-9","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T16:03:09Z","timestamp":1659542589000},"page":"1304-1313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7381-6858","authenticated-orcid":false,"given":"T. M. L.","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Samim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. M.","family":"Speetjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. H.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"El-Sanosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Maschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. K.","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L. A.","family":"Dewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Goeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. C.","family":"Burgmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"issue":"9","key":"3225_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","volume":"118","author":"AD Singh","year":"2011","unstructured":"Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881\u20135.","journal-title":"Ophthalmology"},{"key":"3225_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctrv.2017.08.009","volume":"60","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Steeb T, Schlager JG, Rosumeck S, Dressler C, Ruzicka T, et al. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review. Cancer Treat Rev. 2017;60:44\u201352.","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"3225_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000495113","volume":"5","author":"LT Xu","year":"2019","unstructured":"Xu LT, Funchain PF, Bena JF, Li M, Tarhini A, Berber E, et al. Uveal melanoma metastatic to the liver: treatment trends and outcomes. Ocul Oncol Pathol. 2019;5(5):323\u201332.","journal-title":"Ocul Oncol Pathol"},{"issue":"5","key":"3225_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1055\/s-0040-1720948","volume":"37","author":"CF Gonsalves","year":"2020","unstructured":"Gonsalves CF, Adamo RD, Eschelman DJ. Locoregional therapies for the treatment of uveal melanoma hepatic metastases. Semin Intervent Radiol. 2020;37(5):508\u201317.","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"3225_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cncr.11872","volume":"100","author":"EC Hsueh","year":"2004","unstructured":"Hsueh EC, Essner R, Foshag LJ, Ye X, Wang HJ, Morton DL. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer. 2004;100(1):122\u20139.","journal-title":"Cancer"},{"issue":"13","key":"3225_CR6","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"1","key":"3225_CR7","doi-asserted-by":"publisher","first-page":"e000331","DOI":"10.1136\/jitc-2019-000331","volume":"8","author":"YG Najjar","year":"2020","unstructured":"Najjar YG, Navrazhina K, Ding F, Bhatia R, Tsai K, Abbate K, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8(1):e000331.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3225_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39(6):599\u2013607.","journal-title":"J Clin Oncol"},{"issue":"6","key":"3225_CR9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats JM, Espinosa E, de la Cruz ML, Varela M, Alonso Carrion L, Martin-Algarra S, et al. Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586\u201398.","journal-title":"J Clin Oncol"},{"issue":"8","key":"3225_CR10","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","volume":"30","author":"L Khoja","year":"2019","unstructured":"Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370\u201380.","journal-title":"Ann Oncol"},{"issue":"6","key":"3225_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","volume":"29","author":"ES Rantala","year":"2019","unstructured":"Rantala ES, Hernberg M, Kivela TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29(6):561\u20138.","journal-title":"Melanoma Res"},{"issue":"4","key":"3225_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.hpb.2019.11.002","volume":"22","author":"A Rowcroft","year":"2020","unstructured":"Rowcroft A, Loveday BPT, Thomson BNJ, Banting S, Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020;22(4):497\u2013505.","journal-title":"HPB (Oxford)"},{"key":"3225_CR13","first-page":"53795","volume":"113","author":"EM de Leede","year":"2016","unstructured":"de Leede EM, Burgmans MC, Martini CH, Tijl FG, van Erkel AR, Vuyk J, et al. Percutaneous hepatic perfusion (PHP) with melphalan as a treatment for unresectable metastases confined to the liver. J Vis Exp. 2016;113:53795.","journal-title":"J Vis Exp."},{"issue":"15","key":"3225_CR14","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2005.00.927","volume":"23","author":"JF Pingpank","year":"2005","unstructured":"Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23(15):3465\u201374.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3225_CR15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, et al. Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol. 2016;23(4):1309\u201319.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"3225_CR16","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1007\/s12325-016-0424-4","volume":"33","author":"A Vogel","year":"2017","unstructured":"Vogel A, Gupta S, Zeile M, von Haken R, Bruning R, Lotz G, et al. Chemosaturation percutaneous hepatic perfusion: a systematic review. Adv Ther. 2017;33(12):2122\u201338.","journal-title":"Adv Ther"},{"issue":"6","key":"3225_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00270-017-1588-2","volume":"40","author":"TJ Vogl","year":"2017","unstructured":"Vogl TJ, Koch SA, Lotz G, Gebauer B, Willinek W, Engelke C, et al. Percutaneous isolated hepatic perfusion as a treatment for isolated hepatic metastases of uveal melanoma: patient outcome and safety in a multi-centre study. Cardiovasc Intervent Radiol. 2017;40(6):864\u201372.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"6","key":"3225_CR18","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/jso.24956","volume":"117","author":"I Karydis","year":"2018","unstructured":"Karydis I, Gangi A, Wheater MJ, Choi J, Wilson I, Thomas K, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117(6):1170\u20138.","journal-title":"J Surg Oncol"},{"issue":"1","key":"3225_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40644-019-0218-4","volume":"19","author":"C Artzner","year":"2019","unstructured":"Artzner C, Mossakowski O, Hefferman G, Grosse U, Hoffmann R, Forschner A, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging. 2019;19(1):31.","journal-title":"Cancer Imaging"},{"key":"3225_CR20","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","volume":"28","author":"TS Meijer","year":"2020","unstructured":"Meijer TS, Burgmans MC, de Leede EM, de Geus-Oei LF, Boekestijn B, Handgraaf HJM, et al. Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study. Ann Surg Oncol. 2020;28:1130\u201341.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"3225_CR21","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1007\/s00270-017-1630-4","volume":"40","author":"EM de Leede","year":"2017","unstructured":"de Leede EM, Burgmans MC, Meijer TS, Martini CH, Tijl FGJ, Vuyk J, et al. Prospective clinical and pharmacological evaluation of the Delcath system\u2019s second-generation (GEN2) hemofiltration system in patients undergoing percutaneous hepatic perfusion with melphalan. Cardiovasc Intervent Radiol. 2017;40(8):1196\u2013205.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"10","key":"3225_CR22","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s00432-017-2461-z","volume":"143","author":"MM Kirstein","year":"2017","unstructured":"Kirstein MM, Marquardt S, Jedicke N, Marhenke S, Koppert W, Manns MP, et al. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol. 2017;143(10):2113\u201321.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"3225_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00270-019-02177-x","volume":"42","author":"TS Meijer","year":"2019","unstructured":"Meijer TS, Burgmans MC, Fiocco M, de Geus-Oei LF, Kapiteijn E, de Leede EM, et al. Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath systems\u2019 second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol. 2019;42(6):841\u201352.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"3225_CR24","first-page":"5672048","volume":"2020","author":"R Br\u00fcning","year":"2020","unstructured":"Br\u00fcning R, Tiede M, Schneider M, Wohlmuth P, Weilert H, Oldhafer K, et al. Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan-long-term overall survival negatively correlates with tumor burden. Radiol Res Pract. 2020;2020:5672048.","journal-title":"Radiol Res Pract"},{"issue":"8","key":"3225_CR25","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1055\/a-1348-1932","volume":"193","author":"CLA Dewald","year":"2021","unstructured":"Dewald CLA, Hinrichs JB, Becker LS, Maschke S, Meine TC, Saborowski A, et al. Chemosaturation with percutaneous hepatic perfusion: outcome and safety in patients with metastasized uveal melanoma. Rofo. 2021;193(8):928\u201336.","journal-title":"Rofo"},{"issue":"1","key":"3225_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/cancers14010118","volume":"14","author":"CLA Dewald","year":"2021","unstructured":"Dewald CLA, Warnke MM, Bruning R, Schneider MA, Wohlmuth P, Hinrichs JB, et al. Percutaneous hepatic perfusion (PHP) with melphalan in liver-dominant metastatic uveal melanoma: the german experience. Cancers (Basel). 2021;14(1):118.","journal-title":"Cancers (Basel)."},{"issue":"6","key":"3225_CR27","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00270-015-1276-z","volume":"39","author":"MC Burgmans","year":"2016","unstructured":"Burgmans MC, de Leede EM, Martini CH, Kapiteijn E, Vahrmeijer AL, van Erkel AR. Percutaneous isolated hepatic perfusion for the treatment of unresectable liver malignancies. Cardiovasc Intervent Radiol. 2016;39(6):801\u201314.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"11","key":"3225_CR28","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1177\/0962280220921889","volume":"29","author":"TA Balan","year":"2020","unstructured":"Balan TA, Putter H. A tutorial on frailty models. Stat Methods Med Res. 2020;29(11):3424\u201354.","journal-title":"Stat Methods Med Res"},{"issue":"11","key":"3225_CR29","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00432-020-03289-5","volume":"146","author":"L Schonfeld","year":"2020","unstructured":"Schonfeld L, Hinrichs JB, Marquardt S, Voigtlander T, Dewald C, Koppert W, et al. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. J Cancer Res Clin Oncol. 2020;146(11):3003\u201312.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3225_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-020-00228-7","volume":"25","author":"A Forkasiewicz","year":"2020","unstructured":"Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25(1):1\u201314.","journal-title":"Cell Mol Biol Lett"},{"key":"3225_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2016.09.009","volume":"68","author":"M Marinkovic","year":"2016","unstructured":"Marinkovic M, Horeweg N, Fiocco M, Peters FP, Sommers LW, Laman MS, et al. Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome. Eur J Cancer. 2016;68:106\u201313.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3225_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye (Lond). 2017;31(2):241\u201357.","journal-title":"Eye (Lond)"},{"issue":"1","key":"3225_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-019-03860-z","volume":"84","author":"EB Souto","year":"2019","unstructured":"Souto EB, Zielinska A, Luis M, Carbone C, Martins-Gomes C, Souto SB, et al. Uveal melanoma: physiopathology and new in situ-specific therapies. Cancer Chemother Pharmacol. 2019;84(1):15\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"3225_CR34","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/cancers11060845","volume":"11","author":"MK van der Kooij","year":"2019","unstructured":"van der Kooij MK, Speetjens FM, van der Burg SH, Kapiteijn E. Uveal versus cutaneous melanoma; same origin, very distinct tumor types. Cancers. 2019;11(6):845.","journal-title":"Cancers"},{"issue":"1","key":"3225_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-022-06036-y","volume":"23","author":"TML Tong","year":"2022","unstructured":"Tong TML, van der Kooij MK, Speetjens FM, van Erkel AR, van der Meer RW, Lutjeboer J, et al. Combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib\/randomized phase II trial. Trials. 2022;23(1):1\u201313.","journal-title":"Trials."}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03225-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-022-03225-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-022-03225-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T22:05:52Z","timestamp":1662674752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-022-03225-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3225"],"URL":"https:\/\/doi.org\/10.1007\/s00270-022-03225-9","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"22 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has obtained IRB approval from the Medical Research Ethics Committee of Leiden, The Hague, Delft.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study has obtained IRB approval from the MREC Leiden The Hague Delft, and the need for informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}